Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders

CNS Neuroscience and Therapeutics

Volumn 17, Issue 6, 2011, Pages 649-660

  Post, Robert M ^a,b   Weiss, Susan R B ^c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b Bipolar Collaborative Network   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Anticonvulsants; Depression; Lithium; Mania; Seizures; Treatment resistance

Indexed keywords

4 AMINOBUTYRIC ACID; AMFEBUTAMONE; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CLONIDINE; DESIPRAMINE; DIAZEPAM; ENKEPHALIN; FLUOXETINE; GABAPENTIN; LAMOTRIGINE; LIOTHYRONINE; LISINOPRIL; LITHIUM; METHYLPHENIDATE; MOOD STABILIZER; NEUROTROPHIN 3; NORTRIPTYLINE; PAROXETINE; PROTEIN C FOS; PROTIRELIN; SERTRALINE; TIOTIXENE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

AMYGDALOID NUCLEUS; ANTICONVULSANT ACTIVITY; BIPOLAR DISORDER; CROSS TOLERANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; HUMAN; KINDLING; LONG TERM CARE; NONHUMAN; RAPID CYCLING BIPOLAR DISORDER; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

AMYGDALA; ANIMALS; ANTICONVULSANTS; BIPOLAR DISORDER; CARBAMAZEPINE; DRUG RESISTANCE; DRUG TOLERANCE; HUMANS; KINDLING, NEUROLOGIC; LITHIUM COMPOUNDS; MOOD DISORDERS; SEIZURES; TRIAZINES; VALPROIC ACID;

EID: 82355175416     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00215.x     Document Type: Review

References (56)

1. Lechin F, Van Der Dijs B, Lechin ME, et al. Pimozide therapy for trigeminal neuralgia. Arch Neurol 1989;46:960-963.
2. Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia. Use of side effects. Arch Neurol 1968;19:129-136.
3. Bonduelle M. Current approaches to the treatment of trigeminal neuralgia. Birkmayer W, editor. Epileptic seizures-behavior-pain. Bern/Stuttgart/Vienna: Hans Huber, 1976;321-326.
4. Taylor JC, Brauer S, Espir ML. Long-term treatment of trigeminal neuralgia with carbamazepine. Postgrad Med J 1981;57:16-18.
5. Frankenburg FR, Tohen M, Cohen BM, Lipinski JF, Jr. Long-term response to carbamazepine: A retrospective study. J Clin Psychopharmacol 1988;8:130-132.
6. Post RM, Leverich GS, Rosoff AS, Altshuler LL. Carbamazepine prophylaxis in refractory affective disorders: A focus on long-term follow-up. J Clin Psychopharmacol 1990;10:318-327.
7. Koukopoulos A, Reginaldi D, Minnai G, Serra G, Pani L, Johnson FN. The long term prophylaxis of affective disorders. Adv Biochem Psychopharmacol 1995;49:127-147.
8. Post RM, Leverich GS. Treatment of bipolar illness: A casebook for clinicians and patients. New York: W.W. Norton & Company; 2008.
9. Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: A 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998;155:30-35.
10. Lieb J, Balter A. Antidepressant tachyphylaxis. Med Hypotheses 1984;15:279-291.
11. Mann JJ. Loss of antidepressant effect with long-term monoamine oxidase inhibitor treatment without loss of monoamine oxidase inhibition. J Clin Psychopharmacol 1983;3:363-366.
12. Post R, Leverich GS, Pazzaglia P, Mikalauskas K, Denicoff K. Lithium tolerance and discontinuation as pathways to refractoriness. Birch N, Padgham C, Hughes M, editors. Lithium in medicine and biology. Lancashire, UK: Marius Press, 1993;71-84.
13. Post RM, Leverich GS, Altshuler L, Mikalauskas K. Lithium-discontinuation-induced refractoriness: Preliminary observations. Am J Psychiatry 1992;149:1727-1729.
14. Tondo L, Baldessarini RJ, Floris G, Rudas N. Effectiveness of restarting lithium treatment after its discontinuation in bipolar I and bipolar II disorders. Am J Psychiatry 1997;154:548-550.
15. Fava GA. The decline of pharmaceutical psychiatry and the increasing role of psychological medicine. Psychother Psychosom 2009;78:220-227.
16. Coryell W, Solomon D, Leon AC, Akiskal HS, Keller MB, Scheftner WA, Mueller T. Lithium discontinuation and subsequent effectiveness. Am J Psychiatry 1998;155:895-898.
17. Grof P, Muller-Oerlinghausen B. A critical appraisal of lithium's efficacy and effectiveness: The last 60 years. Bipolar Disord 2009;11(Suppl 2):10-19.
18. Maj M. Lithium discontinuation. Am J Psychiatry 1999;156:1130.
19. Bauer M. Refractoriness induced by lithium discontinuation despite adequate serum lithium levels. Am J Psychiatry 1994;151:1522.
20. Vieta E, Manuel Goikolea J, Martinez-Aran A, et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J Clin Psychiatry 2006;67:473-477.
21. Kishimoto A, Kamata K, Sugihara T, Ishiguro S, Hazama H, Mizukawa R, Kunimoto N. Treatment of depression with clonazepam. Acta Psychiatrica Scandinavica 1988;77:81-86.
22. Singh A, Guberman AH, Boisvert D. Clobazam in long-term epilepsy treatment: Sustained responders versus those developing tolerance. Epilepsia 1995;36:798-803.
23. Post RM, Altshuler L, Frye MA, et al. Complexity of pharmacological treatment required for sustained improvement in outpatients with bipolar disorder. J Clin Psychiatry 2010;71:1176-1186.
24. Racine R. Kindling: The first decade. Neurosurgery 1978;3:234-252.
25. Goddard GV, McIntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation. Experimental Neurology 1969;25:295-330.
26. Weiss SR, Clark M, Rosen JB, Smith MA, Post RM. Contingent tolerance to the anticonvulsant effects of carbamazepine: Relationship to loss of endogenous adaptive mechanisms. Brain Res 1995;20:305-325.
27. Weiss SR, Haas K, Post RM. Contingent tolerance to carbamazepine is associated with lowering of amygdala-kindled seizure thresholds. Exp Neurol 1991;114:300-306.
28. Weiss SRB, Post RM. Contingent tolerance to the anticonvulsant effects of carbamazepine: Implications for Neurology and Psychiatry. Canger R, Sacchetti E, Perini G, Canevini MP, editors. Carbamazepine: A bridge between epilepsy and psychiatric disorders. Origggio: CIBA-Geigy, 1990;7-32.
29. Weiss SR, Post RM. Development and reversal of contingent inefficacy and tolerance to the anticonvulsant effects of carbamazepine. Epilepsia 1991a;32:140-145.
30. Krupp E, Heynen T, Li XL, Post RM, Weiss SR. Tolerance to the anticonvulsant effects of lamotrigine on amygdala kindled seizures: Cross-tolerance to carbamazepine but not valproate or diazepam. Exp Neurol 2000;162:278-289.
31. Postma T, Krupp E, Li XL, Post RM, Weiss SR. Lamotrigine treatment during amygdala-kindled seizure development fails to inhibit seizures and diminishes subsequent anticonvulsant efficacy. Epilepsia 2000;41:1514-1521.
32. Weiss SR, Post RM. Contingent tolerance to carbamazepine: A peripheral-type benzodiazepine mechanism. Eur J Pharmacol 1991b;193:159-163.
33. Loscher W, Schwark WS. Development of tolerance to the anticonvulsant effect of diazepam in amygdala-kindled rats. Exp Neurol 1985;90:373-384.
34. Mana M, Pinel J, Kim C. Contingent tolerance to diazepam's anticonvulsant effect on amygdaloid kindled seizures in the rat. Soc Neurosci Abstr 1986;12:1564 (No. 422.11).
35. Pinel JP, Mana MJ, Renfrey G. Contingent tolerance to the anticonvulsant effects of alcohol. Alcohol (Fayetteville, NY). 1985;2:495-499.
36. Loscher W, Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 2006;47:1253-1284.
37. Post RM, Zhang Z, Weiss SRB, Xing G, Obeng K. Contingent tolerance and cross tolerance to anticonvulsant effects in amygdala-kindled seizures: Mechanistic and clinical implications. Corcoran M, Moshe S, editors. Kindling. New York: Springer, 2005;305-314.
38. Rosen JB, Weiss SR, Post RM. Contingent tolerance to carbamazepine: Alterations in TRH mRNA and TRH receptor binding in limbic structures. Brain Res 1994;651:252-260.
39. Clark M, Massenburg GS, Weiss SR, Post RM. Analysis of the hippocampal GABAA receptor system in kindled rats by autoradiographic and in situ hybridization techniques: Contingent tolerance to carbamazepine. Brain Res Mol Brain Res. 1994;26:309-319.
40. Wan RQ, Noguera EC, Weiss SR. Anticonvulsant effects of intra-hippocampal injection of TRH in amygdala kindled rats. Neuroreport 1998;9:677-682.
41. Kubek MJ, Low WC, Sattin A, Morzorati SL, Meyerhoff JL, Larsen SH. Role of TRH in seizure modulation. Ann N Y Acad Sci 1989;553:286-303.
42. Post RM, Weiss SR. Ziskind-Somerfeld Research Award 1992. Endogenous biochemical abnormalities in affective illness: Therapeutic versus pathogenic. Biol Psychiatry 1992;32:469-484.
43. Post RM, Weiss SR. A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. Mol Neurobiol 1996;13:33-60.
44. Post RM. Animal models of mood disorders: Kindling as model of affective illness progression. Schachter S, Holmes G, Trenite D, editors. Behavioral aspects of epilepsy: Principles and practice. New York: Demos, 2008;19-27.
45. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev 2007;31:858-873.
46. Post RM, Kauer-Sant'Anna M. An introduction to the neurobiology of bipolar illness onset, recurrence, and progression. Yatham LNea, editor. Neurobiology and treatment of bipolar illness. 2010, in press.
47. Covington HE, 3rd, Maze I, LaPlant QC, et al. Antidepressant actions of histone deacetylase inhibitors. J Neurosci 2009;29:11451-11460.
48. Krishnan V, Han MH, Graham DL, et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 2007;131:391-404.
49. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nature Neurosci 2006;9:519-525.
50. Post RM, Miklowitz D. The role of stress in the onset, course, and progression of bipolar illness and its comorbidites: Implications for therapeutics. Miklowitz D, Cicchetti D, editors. Bipolar disorder: A developmental psychopathology perspective. New York: Guilford Publication Inc., 2010;370-413.
51. Zhang ZJ, Russell S, Obeng K, Postma T, Obrocea G, Weiss SR, Post RM. Coadministration of gabapentin or MK-801 with lamotrigine slows tolerance to its anticonvulsant effects on kindled seizures. Pharmacol Biochem Behav 2003a;74:565-571.
52. Pazzaglia PJ, Post RM. Contingent tolerance and reresponse to carbamazepine: A case study in a patient with trigeminal neuralgia and bipolar disorder. J Neuropsychiatry Clin Neurosci 1992;4:76-81.
53. Zhang ZJ, Xing GQ, Russell S, Obeng K, Post RM. Unidirectional cross-tolerance from levetiracetam to carbamazepine in amygdala-kindled seizures. Epilepsia 2003b;44:1487-1493.
54. Weiss SR, Post RM, Sohn E, Berger A, Lewis R. Cross-tolerance between carbamazepine and valproate on amygdala-kindled seizures. Epilepsy Res 1993b;16:37-44.
55. Azar NJ, Lagrange AH, Wang L, Song Y, Abou-Khalil BW. Transient improvement after brief antiepileptic drug withdrawal in the epilepsy monitoring unit-possible relationship to AED tolerance. Epilepsia 2010;51:811-817.
56. Post RM, Luckenbaugh DA. Unique design issues in clinical trials of patients with bipolar affective disorder. J Psychiatric Res 2003;37:61-73.